Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: Systematic analysis of the literature and meta-analysis

Annals of the Rheumatic Diseases

Volumn 77, Issue 4, 2018, Pages 515-522

  Henaux, Sophie ^a,b   Ruyssen Witrand, Adeline ^a,b   Cantagrel, Alain ^a,b   Barnetche, Thomas ^c   Fautrel, Bruno ^d   Filippi, Nathalie ^e   Lukas, Cédric ^e   Raffeiner, Bernd ^f   Rossini, Maurizio ^g   Degboé, Yannick ^a,b   Constantin, Arnaud ^a,b  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c HÔPITAL PELLEGRIN   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

Author keywords

das28; dmards (biologic); rheumatoid arthritis

Indexed keywords

BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUG; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ALLERGIC REACTION; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG INDICATION; HIGH RISK PATIENT; HUMAN; LOW DISEASE ACTIVITY; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RADIOGRAPHIC PROGRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FEMALE; MAINTENANCE CHEMOTHERAPY; MALE; RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; RADIOGRAPHY; RISK FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 85044825981     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212423     Document Type: Article

References (36)

1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
2. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
3. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
4. Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
5. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
6. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
7. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
8. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75:1428-37.
9. Singh JA, Saag KG, Bridges SL, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2015;2016:1-26.
10. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and metaanalysis. Lancet 2015;386:258-65.
11. Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361-8.
12. van Herwaarden N, den Broeder AA, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014:CD010455.
13. Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015;42:2012-22.
14. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
15. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
16. Chatzidionysiou K, Turesson C, Teleman A, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open 2016;2:e000133.
17. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59-67.
18. Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: A pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 2016;68:1810-7.
19. R affeiner B, Botsios C, Ometto F, et al. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol 2015;33:63-8.
20. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
21. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
22. T akeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 2015;54:683-91.
23. T anaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
24. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389.
25. van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.
26. Weinblatt ME, Bingham CO, Burmester GR, et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis Rheumatol 2017;69:1937-48.
27. Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis 2015;74:564-8.
28. Yamanaka H, Nagaoka S, Lee SK, et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol 2016;26:651-61.
29. Botsios C, Furlan A, Ostuni P, et al. Effects of low-dose etanercept in maintaining DASremission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:54.
30. Galloway JB, Kingsley G, Ma M, et al. SAT0150 optimising treatment with tnf inhibitors in rheumatoid arthritis with different dose tapering strategies: The opttira trial:. Ann Rheum Dis 2015;74:706. 1-706.
31. Giollo A, Viapiana O, Orsolini G, et al. Ab0436 persistence of clinical remission by a decreased treatment regimen of 4 mg/kg intravenous tocilizumab: A Randomized Clinical Trial. Ann Rheum Dis 2015;74:1040.
32. O kano T, Inui K, Tada M, et al. FRI0137 medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity-kabuki study-. Ann Rheum Dis 2015;74:471. 1-471.
33. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016;75:45-51.
34. T anaka Y, Yamanaka H, Ishiguro N, et al. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study. RMD Open 2016;2:e000189.
35. Aletaha D, Snedecor SJ, Ektare V, et al. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. Clinicoecon Outcomes Res 2017;9:451-8.
36. Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, et al. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Expert Opin Biol Ther 2014;14:145-50.